BDSX vs DGX
BDSX: Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies. DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals.
Side-by-side fundamentals
| Metric | BDSX | DGX | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $22.32 | $227.90 | |
| Market cap as of 2026-07-24 | $222M | $24.9B | |
| P/E as of 2026-07-24 | n/a | 24.34 | |
| PEG as of 2026-07-24 | n/a | 2.41 | |
| Net margin as of 2026-07-24 | -33.3% | +9.1% | DGX higher |
| Gross margin as of 2026-07-24 | +82.1% | +33.3% | BDSX higher |
| Operating margin as of 2026-07-24 | -25.9% | +14.3% | DGX higher |
| ROE as of 2026-07-24 | -375.1% | +14.1% | DGX higher |
| ROA as of 2026-07-24 | -35.6% | +6.3% | DGX higher |
| Debt / equity as of 2026-07-24 | 5.09 | 0.77 | DGX lower |
| Revenue growth (YoY) as of 2026-07-24 | +29.1% | +11.0% | BDSX higher |
| Revenue CAGR (3y) SEC XBRL | +32.3% | +3.7% | BDSX higher |
| Dividend yield as of 2026-07-24 | n/a | +1.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-24 | 0.58 | 0.54 | |
| 1-year return as of 2026-07-23 close | +197.1% | +33.7% | BDSX higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.